(CercleFinance.com) – RBC reaffirms its ‘performance in line with the sector’ recommendation and its price target of 120 euros on Ipsen, after the presentation of positive phase III data concerning its Cabometyx in stage-stage prostate cancer advance.
While full data is still required to assess its potential, RBC believes ‘strong data could support a significant boost to sales of Cabometyx, currently driven by its use in the context of kidney cancer’.
‘In the meantime, Cabometyx will remain an important growth engine for Ipsen, particularly in front-line kidney cancer’, judge RBC, which anticipates sales of 546 million euros this year (+22%), then a peak of 786 million by 2028.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
